Увійти

Готові списки джерел за темами / Immunogeni / Книги

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Immunogeni.

Книги з теми "Immunogeni"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-25 книг для дослідження на тему "Immunogeni".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте книги для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Koprowski, Hilary, and Fritz Melchers, eds. Peptides as Immunogens. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71440-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Lawson, David Alexander. Identification of immunogenic proteins of litomosoides carinii (Nematoda, Filarioidea). Salford: University of Salford, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Peptides as Immunogens. Berlin: Springer-Verlag, 1986.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Melchers, Fritz, and Hilary Koprowski. Peptides As Immunogens. Springer London, Limited, 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Melchers, Fritz, and Hilary Koprowski. Peptides As Immunogens. Springer, 2011.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Kitazawa, Haruki, Susana Alvarez, and Julio Villena. Probiotics: Immunobiotics and Immunogenics. Taylor & Francis Group, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Kitazawa, Haruki, Susana Alvarez, and Julio Villena. Probiotics: Immunobiotics and Immunogenics. Taylor & Francis Group, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Probiotics immunobiotics and immunogenics. CRC Press, 2014.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Bruce, Simon. Probiotics: Immunobiotics and Immunogenics. Murphy & Moore Publishing, 2022.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Kitazawa, Haruki. Probiotics: Immunobiotics and Immunogenics. Taylor & Francis Group, 2013.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Koprowski, H. Peptides As Immunogens (Current Topics in Microbiology and Immunology). Springer, 1986.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Agin, Tonia S. Immunogenic potential of temperature-sensitive mutants of Escherichia coli. 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Garg, Abhishek D., and Patrizia Agostinis, eds. Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-838-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Cai, Ann. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. 2012.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Ruud, Even. Toward a Sociology of Music Therapy: Musicking As a Cultural Immunogen. Barcelona Publishers, 2020.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Ltd, ICON Group. IMMUNOGEN, INC.: International Competitive Benchmarks and Financial Gap Analysis (Financial Performance Series). 2nd ed. Icon Group International, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Ltd, ICON Group. IMMUNOGEN, INC.: Labor Productivity Benchmarks and International Gap Analysis (Labor Productivity Series). 2nd ed. Icon Group International, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Petrov, R. V. Immunology: Cell Interactions, Myelopeptides Artificial Immunogens (Soviet Medical Reviews Section D, Immunology Reviews, Vol 1). Routledge, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Protocol to evaluate the safety and efficacy of immunogens against bovine anaplasmosis and babesiasis [i.e., babesiosis]. Santiago, Chile: FAO Regional Office for Latin America and the Caribbean, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Petrov, R. V. Physico-Chemical Criteria for the Construction of Artificial Immunomodulators and Immunogens on the Basis of Polyelectrolyte Complexes. Routledge, 1992.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Kloning ekspresi dan karakterisasi protein domain immunogenik pfsera isolat Indonesia: Suatu calon subunit vaksin malaria khas Indonesia. Surabaya: Lembaga Penelitian dan Pengabdian Kepada Masyarakat, Universitas Airlangga, 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Lavoué, Vincent, Patrick Legembre, Jean Levêque, Fabrice Foucher, Sébastien Henno, and Florian Cabillic. Ovarian Cancer Immunity. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0003.

Повний текст джерела

Анотація:

Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no substantial decrease in the death rates due to EOC in the past three decades. Thus, basic knowledge regarding ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC. Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response to EOC in patients. Clinical data demonstrate that an anti-tumor immune response and immune evasion mechanisms are correlated with a better and lower survival, respectively, providing evidence for the immunoediting hypothesis in EOC. This chapter focuses on the immune response and immune suppression in EOC.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Stein, Matthew A. Lymphadenopathy. Edited by Christoph I. Lee, Constance D. Lehman, and Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0051.

Повний текст джерела

Анотація:

Lymphadenopathy is a pathological or abnormal state of one or more lymph nodes in a nodal basin that occurs in response to pathogens, immunogens, or malignant cells that are detected within the lymph. Malignant lymphadenopathy may be detected by physical exam and/or imaging findings, but it is ultimately confirmed or excluded by histological evaluation. This chapter, appearing in the section on nipple, skin, and lymph nodes, reviews key imaging and clinical features, imaging protocols and pitfalls, differential diagnoses, and management recommendations of lymphadenopathy detected by mammography, tomosynthesis, and ultrasound (US). Topics include the anatomy and physiology of breast lymphatic function, the anatomy and imaging features of lymph nodes, differential diagnosis of lymphadenopathy, and the imaging assessment of the axillary nodal basin in the context of known breast cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Drerup, Justin M., Curtis A. Clark, and Tyler J. Curiel. Clinical Trials of Ovarian Cancer Immunotherapy and Future Directions. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0013.

Повний текст джерела

Анотація:

Ovarian cancer (OC) is an immunogenic tumor and among the first where measures of anti-tumor immunity correlated with improved survival. Thus, immunotherapy could be a viable OC treatment modality. Nonetheless, clinical OC immunotherapy trials have demonstrated only modest successes at best, and there is currently no Food and Drug Administration (FDA)approved OC immune therapy despite recent successes in other carcinomas and lymphomas and FDA-approved immunotherapy agents for them. New data suggest specific impediments to effective de novo and treatment-induced anti-OC immunity and support the concept that effective, tolerable OC immunotherapy could be developed based on these newer insights. This chapter reviews the history of OC immunotherapy, highlights important discoveries in OC-related immune dysfunction, covers promising recent developments, highlights newer and ongoing clinical trials, and speculates on future directions that could lead to improved OC immunotherapy approaches.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Vaheri, Antti, James N. Mills, Christina F. Spiropoulou, and Brian Hjelle. Hantaviruses. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198570028.003.0035.

Повний текст джерела

Анотація:

Hantaviruses (genus Hantavirus, family Bunyaviridae) are rodent- and insectivore-borne zoonotic viruses. Several hantaviruses are human pathogens, some with 10-35% mortality, and cause two diseases: hemorrhagic fever with renal syndrome (HFRS) in Eurasia, and hantavirus cardiopulmonary syndrome (HCPS) in the Americas. Hantaviruses are enveloped and have a three-segmented, single-stranded, negative-sense RNA genome. The L gene encodes an RNA-dependent RNA polymerase, the M gene encodes two glycoproteins (Gn and Gc), and the S gene encodes a nucleocapsid protein. In addition, the S genes of some hantaviruses have an NSs open reading frame that can act as an interferon antagonist. Similarities between phylogenies have suggested ancient codivergence of the viruses and their hosts to many authors, but increasing evidence for frequent, recent host switching and local adaptation has led to questioning of this model. Infected rodents establish persistent infections with little or no effect on the host. Humans are infected from aerosols of rodent excreta, direct contact of broken skin or mucous membranes with infectious virus, or rodent bite. One hantavirus, Andes virus, is unique in that it is known to be transmitted from person-to-person. HFRS and HCPS, although primarily affecting kidneys and lungs, respectively, share a number of clinical features, such as capillary leakage, TNF-, and thrombocytopenia; notably, hemorrhages and alterations in renal function also occur in HCPS and cardiac and pulmonary involvement are not rare in HFRS. Of the four structural proteins, both in humoral and cellular immunity, the nucleocapsid protein appears to be the principal immunogen. Cytotoxic T-lymphocyte responses are seen in both HFRS and HCPS and may be important for both protective immunity and pathogenesis. Diagnosis is mainly based on detection of IgM antibodies although viral RNA (vRNA) may be readily, although not invariably, detected in blood, urine and saliva. For sero/genotyping neutralization tests/RNA sequencing are required. Formalin-inactivated vaccines have been widely used in China and Korea but not outside Asia. Hantaviruses are prime examples of emerging and re-emerging infections and, given the limited number of rodents and insectivores thus far studied, it is likely that many new hantaviruses will be detected in the near future.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!